LOXL2 and cancer: Hypoxia is a dominant regulator of HIF‐1α and LOXL2 (HIF‐1α directly transcriptional target) in the progression of various cancers.23 In PC, targeting HIF‐1α and LOXL2 are widely believed as therapeutic strategies to prevention in tumorigenesis of this disease.